<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="48a98150-1118-4dab-8637-80ad223e24a2"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use DICYCLOMINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for DICYCLOMINE HYDROCHLORIDE TABLETS.<br/>
      <br/> DICYCLOMINE HYDROCHLORIDE tablets, for oral use<br/> Initial U.S. Approval: 1950<br/>
   </title>
   <effectiveTime value="20250320"/>
   <setId root="09f0bc6a-5aea-4618-8b71-22a2f0d036f8"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="791119022" root="1.3.6.1.4.1.519.1"/>
            <name>Preferred Pharmaceuticals Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="791119022" root="1.3.6.1.4.1.519.1"/>
                  <name>Preferred Pharmaceuticals Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="791119022" root="1.3.6.1.4.1.519.1"/>
                        <name>Preferred Pharmaceuticals Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="REPACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68788-8581" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="87d2e6ea-d2ee-4e22-9d33-8bcfe431b6b6"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20240206"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68788-8581" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dicyclomine Hydrochloride</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Dicyclomine Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="59651-720" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="CQ903KQA31" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DICYCLOMINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="4KV4X8IF6V" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DICYCLOMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68788-8581-3" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20240206"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA040317" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240206"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLUE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">D20</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="30a384bc-8d8f-48e1-9840-21e8e4d3d93e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Dicyclomine hydrochloride is indicated for the treatment of patients with functional bowel/ irritable bowel syndrome.</paragraph>
               </text>
               <effectiveTime value="20240206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Dicyclomine is an antispasmodic and anticholinergic (antimuscarinic) agent indicated for the treatment of functional bowel/irritable bowel syndrome (<linkHtml href="#_RefSection_1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="df677ea3-03bb-4e2b-a3f4-1edac79fda55"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Dosage must be adjusted to individual patient needs.</paragraph>
               </text>
               <effectiveTime value="20240206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Dosage for dicyclomine must be adjusted to individual patient needs (<linkHtml href="#_RefSection_2">2</linkHtml>).</paragraph>
                        <paragraph>If a dose is missed, patients should continue the normal dosing schedule (<linkHtml href="#_RefSection_2">2</linkHtml>). </paragraph>
                        <paragraph>
                           <content styleCode="bold">Oral in adults (<linkHtml href="#Section_2.1">2.1</linkHtml>):</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Starting dose: 20 mg 4 times a day. After a week treatment with the starting dose, the dose may be escalated to 40 mg 4 times a day, unless side effects limit dosage escalation</item>
                           <item>
                              <caption>•</caption>Discontinue dicyclomine if efficacy not achieved or side effects require doses less than 80 mg per day after 2 weeks of treatment</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="35d764a2-853b-4ca3-b7d8-f09d21d0247e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Oral Dosage and Administration in Adults</title>
                     <text>
                        <paragraph>The recommended initial dose is 20 mg 4 times a day. </paragraph>
                        <paragraph>After one week treatment with the initial dose, the dose may be increased to 40 mg 4 times a day unless side effects limit dosage escalation. </paragraph>
                        <paragraph>If efficacy is not achieved within 2 weeks or side effects require doses below 80 mg per day, the drug should be discontinued. Documented safety data are not available for doses above 80 mg daily for periods longer than 2 weeks.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="621f5ea3-9d0d-442b-b81b-5846c65b7690"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Dicyclomine hydrochloride tablets, USP are available containing 20 mg of dicyclomine hydrochloride, USP.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>The 20 mg tablets are a blue, round, flat-faced, beveled edge tablet debossed with D 20 on one side of the tablet and blank on the other side.</item>
                  </list>
               </text>
               <effectiveTime value="20240206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Dicyclomine hydrochloride tablets 20 mg (<linkHtml href="#Section_3">3</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="d38522b0-f65d-4754-b743-ebfea165fe8e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Dicyclomine hydrochloride is contraindicated in infants less than 6 months of age <content styleCode="italics">[see <linkHtml href="#Section_8.4">Use in Specific Populations (8.4)</linkHtml>],</content> nursing mothers <content styleCode="italics">[see <linkHtml href="#Section_8.3">Use in Specific Populations (8.3)</linkHtml>]</content> and in patients with:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>unstable cardiovascular status in acute hemorrhage</item>
                     <item>
                        <caption>•</caption>myasthenia gravis <content styleCode="italics">[see <linkHtml href="#Section_5.3">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>glaucoma <content styleCode="italics">[see <linkHtml href="#Section_6.3">Adverse Reactions (6.3)</linkHtml> and <linkHtml href="#Section_7.1">Drug Interactions (7.1)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>obstructive uropathy <content styleCode="italics">[see <linkHtml href="#Section_5.7">Warnings and Precautions (5.8)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>obstructive disease of the gastrointestinal tract <content styleCode="italics">[see <linkHtml href="#Section_5.4">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>severe ulcerative colitis <content styleCode="italics">[see <linkHtml href="#Section_5.6">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>reflux esophagitis</item>
                  </list>
               </text>
               <effectiveTime value="20240206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Infants less than 6 months of age (<linkHtml href="#Section_4">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Nursing mothers (<linkHtml href="#Section_4">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Unstable cardiovascular status in acute hemorrhage (<linkHtml href="#Section_4">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Myasthenia gravis (<linkHtml href="#Section_4">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Glaucoma (<linkHtml href="#Section_4">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Obstructive uropathy (<linkHtml href="#Section_4">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Obstructive disease of the gastrointestinal tract (<linkHtml href="#Section_4">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Severe ulcerative colitis (<linkHtml href="#Section_4">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Reflux esophagitis (<linkHtml href="#Section_4">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="73571c3d-5209-48f8-aa05-8a72e0d654f1"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20240206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Cardiovascular conditions</content>: worsening of conditions (<linkHtml href="#Section_5.1">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Peripheral and central nervous system</content>: heat prostration can occur with drug use (fever and heat stroke due to decreased sweating); drug should be discontinued and supportive measures instituted (<linkHtml href="#Section_5.2">5.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Psychosis and delirium have been reported in patients sensitive to anticholinergic drugs (such as elderly patients and/or in patients with mental illness):</content> signs and symptoms resolve within 12 to 24 hours after discontinuation of dicyclomine (<linkHtml href="#Section_5.2">5.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Myasthenia Gravis</content>: overdose may lead to muscular weakness and paralysis. Dicyclomine should be given to patients with myasthenia gravis only to reduce adverse muscarinic effects of an anticholinesterase (<linkHtml href="#Section_5.3">5.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Incomplete intestinal obstruction</content>: diarrhea may be an early symptom especially in patients with ileostomy or colostomy. Treatment with dicyclomine would be inappropriate and possibly fatal (<linkHtml href="#Section_5.4">5.5</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Salmonella dysenteric patients</content>: due to risk of toxic megacolon (<linkHtml href="#Section_5.5">5.6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Ulcerative colitis</content>: Dicyclomine should be used with caution in these patients; large doses may suppress intestinal motility or aggravate the serious complications of toxic megacolon (<linkHtml href="#Section_5.6">5.7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Prostatic hypertrophy</content>: Dicyclomine should be used with caution in these patients; may lead to urinary retention (<linkHtml href="#Section_5.7">5.8</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Hepatic and renal disease</content>: should be used with caution (<linkHtml href="#Section_5.8">5.9</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Geriatric</content>: use with caution in elderly who may be more susceptible to dicyclomine’s adverse events (<linkHtml href="#Section_5.9">5.10</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="f1275c84-4d17-4fc2-9aae-c044f0982ad6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Cardiovascular Conditions</title>
                     <text>
                        <paragraph>Dicyclomine hydrochloride needs to be used with caution in conditions characterized by tachyarrhythmia such as thyrotoxicosis, congestive heart failure and in cardiac surgery, where they may further accelerate the heart rate. Investigate any tachycardia before administration of dicyclomine hydrochloride. Care is required in patients with coronary heart disease, as ischemia and infarction may be worsened, and in patients with hypertension <content styleCode="italics">[see <linkHtml href="#Section_6.3">Adverse Reactions (6.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="47275b99-e28b-4de5-8d3f-8b4befdd6daa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Peripheral and Central Nervous System</title>
                     <text>
                        <paragraph>The peripheral effects of dicyclomine hydrochloride are a consequence of their inhibitory effect on muscarinic receptors of the autonomic nervous system. They include dryness of the mouth with difficulty in swallowing and talking, thirst, reduced bronchial secretions, dilatation of the pupils (mydriasis) with loss of accommodation (cycloplegia) and photophobia, flushing and dryness of the skin, transient bradycardia followed by tachycardia, with palpitations and arrhythmias, and difficulty in micturition, as well as reduction in the tone and motility of the gastrointestinal tract leading to constipation <content styleCode="italics">[see <linkHtml href="#_RefSection_6">Adverse Reactions (6)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>In the presence of high environmental temperature heat prostration can occur with drug use (fever and heat stroke due to decreased sweating). It should also be used cautiously in patients with fever. If symptoms occur, the drug should be discontinued and supportive measures instituted. Because of the inhibitory effect on muscarinic receptors within the autonomic nervous system, caution should be taken in patients with autonomic neuropathy. Central nervous system (CNS) signs and symptoms include confusional state, disorientation, amnesia, hallucinations, dysarthria, ataxia, coma, euphoria, fatigue, insomnia, agitation and mannerisms and inappropriate affect.</paragraph>
                        <paragraph>Psychosis and delirium have been reported in sensitive individuals (such as elderly patients and/ or in patients with mental illness) given anticholinergic drugs. These CNS signs and symptoms usually resolve within 12 to 24 hours after discontinuation of the drug.</paragraph>
                        <paragraph>Dicyclomine may produce drowsiness, dizziness or blurred vision. The patient should be warned not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery or performing hazardous work while taking dicyclomine.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="dd22647a-921e-4a9d-8263-4d4801454ea7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Myasthenia Gravis</title>
                     <text>
                        <paragraph>With overdosage, a curare-like action may occur (i.e., neuromuscular blockade leading to muscular weakness and possible paralysis). It should not be given to patients with myasthenia gravis except to reduce adverse muscarinic effects of an anticholinesterase <content styleCode="italics">[see <linkHtml href="#Section_4">Contraindications (4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="7df3a11a-d665-480f-8ef7-fe7fbac18062"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Intestinal Obstruction</title>
                     <text>
                        <paragraph>Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful <content styleCode="italics">[see <linkHtml href="#Section_4">Contraindications (4)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Rarely development of Ogilvie’s syndrome (colonic pseudoobstruction) has been reported. Ogilvie’s syndrome is a clinical disorder with signs, symptoms and radiographic appearance of an acute large bowel obstruction but with no evidence of distal colonic obstruction</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="c907efe7-2f07-4fe2-bfb6-c2eb0cce0c1b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Toxic Dilatation of Intestinemegacolon</title>
                     <text>
                        <paragraph>Toxic dilatation of intestine and intestinal perforation is possible when anticholinergic agents are administered in patients with Salmonella dysentery.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.6">
                     <id root="ddae48eb-5490-451c-bcf6-719bbf6e4c0b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Ulcerative Colitis</title>
                     <text>
                        <paragraph>Caution should be taken in patients with ulcerative colitis. Large doses may suppress intestinal motility to the point of producing a paralytic ileus and the use of this drug may precipitate or aggravate the serious complication of toxic megacolon <content styleCode="italics">[see <linkHtml href="#Section_6.3">Adverse Reactions (6.3)</linkHtml>]. </content>Dicyclomine is contraindicated in patients with severe ulcerative colitis <content styleCode="italics">[see <linkHtml href="#Section_4">Contraindications (4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.7">
                     <id root="cf049acb-b5e8-405d-89b5-67cce9fe3e9d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Prostatic Hypertrophy</title>
                     <text>
                        <paragraph>Dicyclomine should be used with caution in patients with known or suspected prostatic enlargement, in whom prostatic enlargement may lead to urinary retention <content styleCode="italics">[see <linkHtml href="#Section_6.3">Adverse Reactions (6.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.8">
                     <id root="f5a75c85-f811-40c6-8b54-89c334e29309"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Hepatic and Renal Disease</title>
                     <text>
                        <paragraph>Dicyclomine should be used with caution in patients with known hepatic and renal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.9">
                     <id root="6f6b26cd-6991-4b40-9e64-c17cfa89cb7b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Geriatric Population</title>
                     <text>
                        <paragraph>Dicyclomine hydrochloride should be used with caution in elderly who may be more susceptible to its adverse effects.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="b8d14b31-d3bd-46fc-a38e-51d36530b5c8"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The pattern of adverse effects seen with dicylomine is mostly related to its pharmacological actions at muscarinic receptors <content styleCode="italics">[see <linkHtml href="#Section_12">Clinical Pharmacology (12)</linkHtml>].</content> They are a consequence of the inhibitory effect on muscarinic receptors within the autonomic nervous system. These effects are dose-related and are usually reversible when treatment is discontinued. </paragraph>
                  <paragraph>The most serious adverse reactions reported with dicyclomine hydrochloride include cardiovascular and central nervous system symptoms <content styleCode="italics">[see <linkHtml href="#Section_5.1">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#Section_5.2">5.3)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most serious adverse reactions include cardiovascular and central nervous system symptoms. The most common adverse reactions (&gt; 5% of patients) are dizziness, dry mouth, vision blurred, nausea, somnolence, asthenia and nervousness (<linkHtml href="#_RefSection_6">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="9575aaba-0a0b-406c-8f4a-3d0f9008ca93"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The data described below reflect exposure in controlled clinical trials involving over 100 patients treated for functional bowel/irritable bowel syndrome with dicyclomine hydrochloride at initial doses of 160 mg daily (40 mg 4 times a day).</paragraph>
                        <paragraph>In these trials most of the side effects were typically anticholinergic in nature and were reported by 61% of the patients. Table 1 presents adverse reactions (<content styleCode="italics">MedDRA 13.0 </content>preferred terms) by decreasing order of frequency in a side-by-side comparison with placebo.</paragraph>
                        <table ID="_RefID0EUEAE" cellpadding="0pt" cellspacing="0pt" width="100%">
                           <caption>Table 1:  Adverse reactions experienced in controlled clinical trials with decreasing order of frequency  </caption>
                           <col width="33%"/>
                           <col width="37%"/>
                           <col width="30%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">MedDRA</content>
                                       <br/>
                                       <content styleCode="bold">Preferred Term</content>
                                       <br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Dicyclomine Hydrochloride (40 mg four times a day) %</content>
                                       <br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Placebo %</content>
                                       <br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Dry Mouth<br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>33<br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>5<br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Dizziness<br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>40<br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>5<br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Vision Blurred<br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>27<br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>2<br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Nausea<br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>14<br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>6<br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Somnolence<br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>9<br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>1<br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Asthenia<br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>7<br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>1<br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Nervousness<br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>6<br/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>2<br/>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Nine percent (9%) of patients were discontinued from dicyclomine because of one or more of these side effects (compared with 2% in the placebo group). In 41% of the patients with side effects, side effects disappeared or were tolerated at the 160 mg daily dose without reduction. A dose reduction from 160 mg daily to an average daily dose of 90 mg was required in 46% of the patients with side effects who then continued to experience a favorable clinical response; their side effects either disappeared or were tolerated.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="79e22435-5a73-453e-9780-f969086c7547"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions, presented by system organ class in alphabetical order, have been identified during post approval use of dicyclomine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">
                                 <content styleCode="italics">Cardiac Disorders:</content>
                              </content> palpitations, tachyarrhythmias</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">
                                 <content styleCode="italics">Eye Disorders: </content>
                              </content>cycloplegia, mydriasis, vision blurred</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">
                                 <content styleCode="italics">Gastrointestinal Disorders:</content>
                              </content> abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, nausea, vomiting</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">
                                 <content styleCode="italics">General Disorders and Administration Site Conditions:</content>
                              </content> fatigue, malaise</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">
                                 <content styleCode="italics">Immune System Disorders:</content>
                              </content> drug hypersensitivity including face edema, angioedema, anaphylactic shock</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">
                                 <content styleCode="italics">Nervous System Disorders:</content>
                              </content> dizziness, headache, somnolence, syncope</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">
                                 <content styleCode="italics">Psychiatric Disorders:</content>
                              </content> As with the other anticholinergic drugs, cases of delirium or symptoms of delirium such as amnesia (or transient global amnesia), agitation, confusional state, delusion, disorientation, hallucination (including visual hallucination) as well as mania, mood altered and pseudodementia, have been reported with the use of dicyclomine. Nervousness and insomnia have also been reported.</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">
                                 <content styleCode="italics">Reproductive System and Breast Disorders:</content>
                              </content> suppressed lactation</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">
                                 <content styleCode="italics">Respiratory, Thoracic and Mediastinal Disorders:</content>
                              </content> dyspnoea, nasal congestion</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">
                                 <content styleCode="italics">Skin and Subcutaneous Tissue Disorder:</content>
                              </content> dermatitis allergic, erythema, rash</item>
                        </list>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.3">
                     <id root="a63b60f8-1a9f-4ba1-ba61-fcec7e4b1999"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.3 Adverse Reactions Reported with Similar Drugs with Anticholinergic/Antispasmodic Action</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Gastrointestinal:</content>
                           </content> anorexia</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Central Nervous System:</content>
                           </content> tingling, numbness, dyskinesia, speech disturbance, insomnia<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">Peripheral Nervous System:</content>
                           </content> With overdosage, a curare-like action may occur (i.e., neuromuscular blockade leading to muscular weakness and possible paralysis)</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Ophthalmologic:</content>
                           </content> diplopia, increased ocular tension</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Dermatologic/Allergic: </content>
                           </content>urticaria, itching and other dermal manifestations</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Genitourinary:</content>
                           </content> urinary hesitancy, urinary retention in patients with prostatic hypertrophy</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Cardiovascular: </content>
                           </content>hypertension</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Respiratory:</content>
                           </content> apnea</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Other:</content>
                           </content> decreased sweating, sneezing, throat congestion, impotence</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="e50ad0b6-4859-452e-8022-b0050a7dd634"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20240206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Antiglaucoma agents</content>: anticholinergics antagonize antiglaucoma agents and may increase intraoccular pressure (<linkHtml href="#Section_7">7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Anticholinergic agents</content>: may affect the gastrointestinal absorption of various drugs; may also increase certain actions or side effects of other anticholinergic drugs (<linkHtml href="#Section_7">7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Antacids</content>: interfere with the absorption of anticholinergic agents (<linkHtml href="#Section_7">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_7.1">
                     <id root="2b976d2c-3f4d-40cc-a140-fd2cb0c1d02f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Antiglaucoma Agents</title>
                     <text>
                        <paragraph>Anticholinergics antagonize the effects of antiglaucoma agents. Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. Use of dicyclomine in patients with glaucoma is not recommended <content styleCode="italics">[see <linkHtml href="#Section_4">Contraindications (4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.2">
                     <id root="39140dcc-afe6-4738-96c2-2aadd53d6ded"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Other Drugs with Anticholinergic Activity</title>
                     <text>
                        <paragraph>The following agents may increase certain actions or side effects of anticholinergic drugs including dicyclomine: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants and other drugs having anticholinergic activity.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.3">
                     <id root="117b2624-5f67-4cff-a0a4-e13aa7da3044"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Other Gastrointestinal Motility Drugs</title>
                     <text>
                        <paragraph>Interaction with other gastrointestinal motility drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.4">
                     <id root="fbd67344-656a-4732-9a7f-caa93043967c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Effect of Antacids</title>
                     <text>
                        <paragraph>Because antacids may interfere with the absorption of anticholinergic agents including dicyclomine, simultaneous use of these drugs should be avoided.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.5">
                     <id root="cac71eb4-7163-48c5-8438-5053bde28ead"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5 Effect on Absorption of Other Drugs</title>
                     <text>
                        <paragraph>Anticholinergic agents may affect gastrointestinal absorption of various drugs by affecting on gastrointestinal motility, such as slowly dissolving dosage forms of digoxin; increased serum digoxin concentration may result.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.6">
                     <id root="0e044a19-be4b-4daa-b7b2-bb63fb7ad36e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.6 Effect on Gastric Acid Secretion</title>
                     <text>
                        <paragraph>The inhibiting effects of anticholinergic drugs on gastric hydrochloric acid secretion are antagonized by agents used to treat achlorhydria and those used to test gastric secretion.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="dba30ea6-321e-49e5-970d-b3328064f1dd"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20240206"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Pregnancy: use only if clearly needed (<linkHtml href="#Section_8.1">8.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Pediatric Use: Safety and effectiveness not established (<linkHtml href="#Section_8.4">8.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Hepatic and renal impairment: caution must be taken with patients with significantly impaired hepatic and renal function (<linkHtml href="#Section_8.6">8.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="e100afd5-abc1-40ec-b119-aeb09445eccd"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pregnancy Category B:</content>
                           </content> Adequate and well-controlled studies have not been conducted with dicyclomine in pregnant women at the recommended doses of 80 mg/day to 160 mg/day. However, epidemiologic studies did not show an increased risk of structural malformations among babies born to women who took products containing dicyclomine hydrochloride at doses up to 40 mg/day during the first trimester of pregnancy. Reproduction studies have been performed in rats and rabbits at doses up to 33 times the maximum recommended human dose based on 160 mg/day (3 mg/kg) and have revealed no evidence of harm to the fetus due to dicyclomine. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.3">
                     <id root="fdfb7bab-9a7d-4601-9796-f0f0b3683541"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph>Dicyclomine is contraindicated in women who are breastfeeding. Dicyclomine hydrochloride is excreted in human milk. Because of the potential for serious adverse reactions in breast-fed infants from dicyclomine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother <content styleCode="italics">[see <linkHtml href="#Section_8.4">Use in Specific Populations (8.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="ecfe1901-df76-4c04-833d-83ff8dd73eec"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established. </paragraph>
                        <paragraph>Dicyclomine is contraindicated in infants less than 6 months of age <content styleCode="italics">[see <linkHtml href="#Section_4">Contraindications (4)</linkHtml>]. </content>There are published cases reporting that the administration of dicyclomine hydrochloride to infants has been followed by serious respiratory symptoms (dyspnea, shortness of breath, breathlessness, respiratory collapse, apnea and asphyxia), seizures, syncope, pulse rate fluctuations, muscular hypotonia, and coma and death, however; no causal relationship has been established.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="9b55e575-8343-487c-8c2d-31c5befa9186"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of dicyclomine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range in adults, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy. </paragraph>
                        <paragraph>Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="8cae27e0-3f6e-4f2e-8891-8ccd61e68385"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Effects of renal impairment on PK, safety and efficacy of dicyclomine have not been studied. Dicyclomine drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Dicyclomine should be administered with caution in patients with renal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.7">
                     <id root="011fe46f-9f8e-4457-9bbe-75e6d6ecd552"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>Effects of renal impairment on PK, safety and efficacy of dicyclomine have not been studied. Dicyclomine should be administered with caution in patients with hepatic impairment.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="00e90898-aa02-410a-a390-3c7ca7a20358"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In case of an overdose, patients should contact a physician, poison control center (1-800-222-1222), or emergency room. </paragraph>
                  <paragraph>The signs and symptoms of overdosage include: headache; nausea; vomiting; blurred vision; dilated pupils; hot, dry skin; dizziness; dryness of the mouth; difficulty in swallowing; and CNS stimulation including convulsion. A curare-like action may occur (i.e., neuromuscular blockade leading to muscular weakness and possible paralysis).</paragraph>
                  <paragraph>One reported event included a 37 year old who reported numbness on the left side, cold fingertips, blurred vision, abdominal and flank pain, decreased appetite, dry mouth and nervousness following ingestion of 320 mg daily (four 20 mg tablets 4 times daily). These events resolved after discontinuing the dicyclomine.</paragraph>
                  <paragraph>The acute oral LD<sub>50</sub> of the drug is 625 mg/kg in mice.</paragraph>
                  <paragraph>The amount of drug in a single dose that is ordinarily associated with symptoms of overdosage or that is likely to be life threatening, has not been defined. The maximum human oral dose recorded was 600 mg by mouth in a 10 month old child and approximately 1500 mg in an adult, each of whom survived. In three of the infants who died following administration of dicyclomine hydrochloride <content styleCode="italics">[see <linkHtml href="#Section_5">Warnings and Precautions (5.1)</linkHtml>],</content> the blood concentrations of drug were 200 ng/mL, 220 ng/mL, and 505 ng/mL.</paragraph>
                  <paragraph>It is not known if dicyclomine is dialyzable.</paragraph>
                  <paragraph>Treatment should consist of gastric lavage, emetics and activated charcoal. Sedatives (e.g., short-acting barbiturates, benzodiazepines) may be used for management of overt signs of excitement. If indicated, an appropriate parenteral cholinergic agent may be used as an antidote.</paragraph>
               </text>
               <effectiveTime value="20240206"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="792a992e-0a96-46a8-934a-d0bbff58c2c8"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Dicyclomine hydrochloride is an antispasmodic and anticholinergic (antimuscarinic) agent.</paragraph>
                  <paragraph>Chemically, dicyclomine hydrochloride is [bicyclohexyl]-1-carboxylic acid, 2-(diethylamino) ethyl ester, hydrochloride with the following structural formula, molecular weight, and molecular formula: </paragraph>
                  <renderMultiMedia ID="id904" referencedObject="C1BF750E-139D-44FE-BBB4-802A8AA9416E"/>
                  <paragraph>Dicyclomine hydrochloride, USP occurs as a white crystalline powder. It is soluble in water, freely soluble in alcohol and chloroform, and very slightly soluble in ether. </paragraph>
                  <paragraph>Dicyclomine hydrochloride tablets, USP for oral administration contain 20 mg of dicyclomine hydrochloride, USP. In addition each tablet contains the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, FD&amp;C Blue No. 1 Aluminum Lake, magnesium stearate, microcrystalline cellulose, pregelatinized starch (corn) and sodium lauryl sulfate. </paragraph>
               </text>
               <effectiveTime value="20240206"/>
               <component>
                  <observationMedia ID="C1BF750E-139D-44FE-BBB4-802A8AA9416E">
                     <text>Chemical Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dicyclomine-str.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="058c3fd1-ffc1-41a2-810a-b45fa8a65381"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20240206"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="27a06759-77ff-44d7-998a-3521d1942058"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Dicyclomine relieves smooth muscle spasm of the gastrointestinal tract. Animal studies indicate that this action is achieved via a dual mechanism:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites with approximately 1/8 the milligram potency of atropine (<content styleCode="italics">in vitro</content>, guinea pig ileum); and</item>
                           <item>
                              <caption>•</caption>a direct effect upon smooth muscle (musculotropic) as evidenced by dicyclomine’s antagonism of bradykinin- and histamine-induced spasms of the isolated guinea pig ileum.</item>
                        </list>
                        <paragraph>Atropine did not affect responses to these two agonists. <content styleCode="italics">In vivo</content> studies in cats and dogs showed dicyclomine to be equally potent against acetylcholine (ACh)- or barium chloride (BaCl<sub>2</sub>)-induced intestinal spasm while atropine was at least 200 times more potent against effects of ACh than BaCl<sub>2</sub>. Tests for mydriatic effects in mice showed that dicyclomine was approximately 1/500 as potent as atropine; antisialagogue tests in rabbits showed dicyclomine to be 1/300 as potent as atropine.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.2">
                     <id root="b526279c-251c-4c22-890c-b0954c2bf9da"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Dicyclomine can inhibit the secretion of saliva and sweat, decrease gastrointestinal secretions and motility, cause drowsiness, dilate the pupils, increase heart rate and depress motor function.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="f48cd13a-46dd-489b-b93e-5f4c0fabe872"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Absorption and Distribution:</content>
                           </content> In man, dicyclomine is rapidly absorbed after oral administration, reaching peak values within 60 to 90 minutes. Mean volume of distribution for a 20 mg oral dose is approximately 3.65 L/kg suggesting extensive distribution in tissues.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Elimination:</content>
                           </content> The metabolism of dicyclomine was not studied. The principal route of excretion is via the urine (79.5% of the dose). Excretion also occurs in the feces, but to a lesser extent (8.4%). Mean half-life of plasma elimination in one study was determined to be approximately 1.8 hours when plasma concentrations were measured for 9 hours after a single dose. In subsequent studies, plasma concentrations were followed for up to 24 hours after a single dose, showing a secondary phase of elimination with a somewhat longer half-life.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="4971d527-de1e-41ec-b81d-24b671fbe41d"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20240206"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="34087e10-0467-48d2-a3f2-28245cf343a0"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term animal studies have not been conducted to evaluate the carcinogenic potential of dicyclomine. In studies in rats at doses of up to 100 mg/kg/day, dicyclomine produced no deleterious effects on breeding, conception or parturition.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="449a83d0-d840-4bea-8db8-53cb397ffb60"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>In controlled clinical trials involving over 100 patients who received drug, 82% of patients treated for functional bowel/irritable bowel syndrome with dicyclomine hydrochloride at initial doses of 160 mg daily (40 mg 4 times daily) demonstrated a favorable clinical response compared with 55% treated with placebo (p &lt; 0.05).</paragraph>
               </text>
               <effectiveTime value="20240206"/>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="e15c9178-518e-4583-80bc-7f8be464808d"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Dicyclomine hydrochloride tablets, USP are available containing 20 mg of dicyclomine hydrochloride, USP.</paragraph>
                  <paragraph>The 20 mg tablets are a blue, round, flat-faced, beveled edge tablet debossed with D 20 on one side of the tablet and blank on the other side. They are available as follows:</paragraph>
                  <paragraph>                        Bottles of 30 tablets                                                  NDC 68788-8581-3</paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">To prevent fading, avoid exposure to direct sunlight.</content>
                  </paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</paragraph>
               </text>
               <effectiveTime value="20240206"/>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="8ff8a8fd-ed6c-4a06-be7c-f891a243c800"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20240206"/>
               <component>
                  <section ID="Section_16.1">
                     <id root="d5377aeb-30de-47cd-a3a5-0d78206995a4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.2 Use in Infants</title>
                     <text>
                        <paragraph>Inform parents and caregivers not to administer dicyclomine in infants less than 6 months of age <content styleCode="italics">[see <linkHtml href="#Section_8.4">Use in Specific Populations (8.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_16.2">
                     <id root="7f42886c-aef8-438a-92a9-9f8abefdbb37"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.3 Use in Nursing Mothers</title>
                     <text>
                        <paragraph>Advise lactating women that dicyclomine should not be used while breastfeeding their infants <content styleCode="italics">[see <linkHtml href="#Section_8.3">Use in Specific Populations (8.3</linkHtml>, <linkHtml href="#Section_8.4">8.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_16.3">
                     <id root="72aced1c-1439-4587-87e3-17ade72b7319"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.4 Peripheral and Central Nervous System</title>
                     <text>
                        <paragraph>In the presence of a high environmental temperature, heat prostration can occur with dicyclomine use (fever and heat stroke due to decreased sweating). If symptoms occur, the drug should be discontinued and a physician contacted. Dicyclomine may produce drowsiness or blurred vision. The patient should be warned not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery or to perform hazardous work while taking dicyclomine<content styleCode="italics"> [see <linkHtml href="#Section_5.2">Warnings and Precautions (5.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Distributed by:<br/>
                           <content styleCode="bold">Aurobindo Pharma USA, Inc.</content>
                           <br/>279 Princeton-Hightstown Road<br/> East Windsor, NJ 08520<br/>
                           <br/> Manufactured by:<br/>
                           <content styleCode="bold">Aurobindo Pharma Limited</content>
                           <br/>Hyderabad-500 032, India<br/>
                           <br/> Revised: 03/2023</paragraph>
                        <paragraph>
                           <content styleCode="bold">Repackaged By: Preferred Pharmaceuticals Inc.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="657af2d2-7e9b-4386-be49-0aebd7fd79e7"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 20 mg </title>
               <text>
                  <paragraph>NDC 68788-8581-3<br/>
                     <br/>
                     <content styleCode="bold"> Dicyclomine Hydrochloride</content>
                     <br/>
                     <content styleCode="bold"> Tablets, USP</content>
                     <br/>
                     <content styleCode="bold"> 20 mg</content>
                     <br/>
                     <br/>
                     <content styleCode="bold">Rx only          </content>
                     <br/>
                     <content styleCode="bold"> AUROBINDO</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Repackaged By: Preferred Pharmaceuticals Inc.</content>
                     <br/>
                  </paragraph>
                  <paragraph>68788-8581-3<br/>
                     <renderMultiMedia ID="id1078" referencedObject="ID_8fd88568-a35d-4eb6-844d-82b3dfc37262"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240206"/>
               <component>
                  <observationMedia ID="ID_8fd88568-a35d-4eb6-844d-82b3dfc37262">
                     <text>Dicyclomine HCl Tablets USP 20mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dicyclomine-fig1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>